Kura Oncology (KURA) Current Assets (2010 - 2026)

Kura Oncology (KURA) has 17 years of Current Assets data on file, last reported at $623.8 million in Q1 2026.

• On a quarterly basis, Current Assets fell 13.87% year-over-year to $623.8 million in Q1 2026; TTM through Mar 2026 was $623.8 million, a 13.87% decrease from a year earlier, with the FY2025 full-year figure at $708.7 million, down 4.86% from the prior year.
• Current Assets for Q1 2026 stood at $623.8 million, down from $708.7 million in the prior quarter.
• Over the last five years, Current Assets for KURA reached as high as $744.8 million in Q4 2024 and fell as low as $416.4 million in Q1 2023.
• Historically, Current Assets has averaged $541.6 million across 5 years, with a median of $487.0 million in 2022.
• Across the five-year window, Current Assets declined 20.5% in 2022 and soared 72.22% in 2024, its largest moves.
• Year by year, Current Assets stood at $446.4 million in 2022, then fell by 3.12% to $432.5 million in 2023, then soared by 72.22% to $744.8 million in 2024, then dropped by 4.86% to $708.7 million in 2025, then decreased by 11.98% to $623.8 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $623.8 million in Q1 2026, $708.7 million in Q4 2025, and $620.7 million in Q3 2025.